No, in fact it's really easy to read. As I've described, the fact the CLTX ligand is currently unresolved is of little immediate importance and will be easily resolved in due course. It is of scientific interest and longer term potentially some clinical interest, hence the abstract to a scientific meeting. CHM agrees it is of little relevance to near-term clinical development as per their ASX releases, so I'm glad you believe them.
Ann: CLTX CAR T PRESENTS POSITIVE INITIAL PHASE 1 CLINICAL DATA, page-29
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $20.21K | 5.053M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2213046 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 13563373 | 20 |
View Market Depth
| Last trade - 15.01pm 24/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |